Peter Greenleaf Sells 195,593 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Stock

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) CEO Peter Greenleaf sold 195,593 shares of the business’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $8.00, for a total transaction of $1,564,744.00. Following the completion of the transaction, the chief executive officer now owns 1,953,892 shares in the company, valued at $15,631,136. This represents a 9.10 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Aurinia Pharmaceuticals Stock Performance

Shares of Aurinia Pharmaceuticals stock opened at $8.67 on Thursday. The firm has a market cap of $1.24 billion, a PE ratio of -57.80 and a beta of 1.22. The firm’s 50-day simple moving average is $8.13 and its 200-day simple moving average is $7.86. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.11 and a current ratio of 5.60. Aurinia Pharmaceuticals Inc. has a 1 year low of $4.71 and a 1 year high of $10.67.

Institutional Investors Weigh In On Aurinia Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. State Street Corp grew its position in shares of Aurinia Pharmaceuticals by 2.3% during the 3rd quarter. State Street Corp now owns 2,945,060 shares of the biotechnology company’s stock valued at $21,587,000 after buying an additional 64,949 shares during the last quarter. Barclays PLC grew its position in shares of Aurinia Pharmaceuticals by 187.6% during the 3rd quarter. Barclays PLC now owns 219,331 shares of the biotechnology company’s stock valued at $1,607,000 after buying an additional 143,072 shares during the last quarter. Blue Trust Inc. grew its position in shares of Aurinia Pharmaceuticals by 3,041.4% during the 4th quarter. Blue Trust Inc. now owns 6,377 shares of the biotechnology company’s stock valued at $57,000 after buying an additional 6,174 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Aurinia Pharmaceuticals during the 3rd quarter valued at about $3,330,000. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Aurinia Pharmaceuticals by 13.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 744,050 shares of the biotechnology company’s stock valued at $5,454,000 after buying an additional 89,940 shares during the last quarter. Institutional investors and hedge funds own 36.83% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, StockNews.com lowered shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 19th.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.